Mir-16 microRNA precursor family

Background

The human miR-16 precursor was discovered through detailed expression profile and Karyotype analyses of patients by Calin and colleagues. Karyotyping of chromosome structures from individuals with B-cell chronic lymphocytic leukaemias (B-CLL) found that more than half have alterations in the 13q14 region. Deletions of this well characterised 1 megabase region of the genome was also observed in approximately 50% of mantle cell lymphoma, up to 40% of multiple myeloma, and 60% of prostate cancers. Comprehensive screenings of the region at the time did not provide consistent evidence of involvement from any of the known genes at the time. Using CD5+ B-lymphocytes, which is known to accumulate with B-CLL progression, the minimal region lost from 13q14 region was scrutinised for regulatory elements. Publicly available sequence databases were used to identify a gene cluster which encodes the homologue to the human miR15 and miR16 from the Caenorhabditis elegans.

Gene targets

In the original publication which identified the action of miR15 and miR16 in the development of B-CLL, Calin and colleagues proposed that miR16 could be the targets with imperfect base pairing for 14 genes. Increased CD5+ B-lymphocytes in CLL suggests the miR16 may be involved in cellular differentiation. In animal models single-stranded microRNA species act by binding to imperfect mRNA complements, typically to the 3' UTR, although targets have also been observed in the coding sequence of the mRNA. Downregulation of miR16 (as well as miR15) was observed in diffuse large B-cell lymphoma. miR16 has been shown to bind to a nine base pair to a complementary sequence in the 3' UTR region of BCL2, which is an anti-apoptotic gene involved in an evolutionarily conserved pathway in programmed cell death. In the nasopharyngeal carcinoma cell line, miR-16 has been shown to target the 3' UTR of vascular endothelial growth factor (VEGF) and repress the expression of VEGF, which is an important angiogenic factor.

Clinical relevance

Altered expression of microRNA-16 has been observed in cancer, including malignancies of the breast, colon, brain , lung, lymphatic system, ovaries, pancreas , prostate and stomach. This difference in expression levels can be used distinguish between cancerous and healthy tissues and to determine clinical prognosis. The fact that pathology is associated with a different expression profile has led to the proposal that disease specific biomarkers can provide potential targets for directed clinical intervention. More recently, there is evidence that in colorectal cancer that the efficacy of treatment with the monoclonal antibody cetuximab can be assessed by the expression pattern of colorectal carcinoma after therapy.

miR-16 and miR-15a are clustered within a 0.5 kbp region in Chromosome 13 (13q14) in humans, a chromosomal region shown to be deleted or down-regulated in approximately more than half of B-CLL, the most prevalent form of leukemia in adults. Carcinogenesis is a gradual process, involving multiple genetic mutations, thus every patient with malignancy presents with a heterogeneous population of cells. The fact that mir-16 microRNA loss is observed in a large proportion of cells indicates the change occurred early in cancer development and a target for therapeutic intervention.

References

References

1. (2002). "Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.". Proc Natl Acad Sci USA.
2. (2009). "Genetic alterations in chronic lymphocytic leukaemia.". Clin Transl Oncol.
3. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ,[[Carlo M. Croce. (2001). "Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene.". Cancer Res.
4. (2001). "Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia.". Blood.
5. (2001). "Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer.". Prostate.
6. (1997). "Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia.". Oncogene.
7. (2001). "Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia.". Cancer Res.
8. (2001). "Comprehensive analysis of a large genomic sequence at the putative B-cell chronic lymphocytic leukaemia (B-CLL) tumour suppresser gene locus.". Mutat Res.
9. (2001). "B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions". Hum Mol Genet.
10. (2002). "Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia". Leukemia.
11. (1999). "B-cell chronic lymphocytic leukemia: a bird of a different feather". J Clin Oncol.
12. (2001). "Identification of novel genes coding for small expressed RNAs". Science.
13. (2001). "An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans". Science.
14. (2001). "An extensive class of small RNAs in Caenorhabditis elegans". Science.
15. (2005). "Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets". Cell.
16. (2005). "Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals". Nature.
17. (2008). "MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation". Nature.
18. (2004). "Accumulation of miR-155 and BIC RNA in human B-cell lymphoma". Proc Natl Acad Sci U S A.
19. (2005). "miR-15 and miR-16 induce apoptosis by targeting BCL2". Proc Natl Acad Sci U S A.
20. (27 December 2006). "MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia". PLOS ONE.
21. (5 March 2008). "The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation". PLOS ONE.
22. (2005). "MicroRNA expression profiles classify human cancers". Nature.
23. Croce CM.. (2009). "Causes and consequences of microRNA dysregulation in cancer". Nat Rev Genet.
24. (2004). "Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers". Proc Natl Acad Sci U S A.
25. (2012). "Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development". Breast Cancer Res.
26. (2003). "Reduced accumulation of specific microRNAs in colorectal neoplasia". Mol Cancer Res.
27. (2008). "MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma". JAMA.
28. (2005). "Extensive modulation of a set of microRNAs in primary glioblastoma". Biochem Biophys Res Commun.
29. (2007). "MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells". Cancer Res.
30. (2004). "Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival". Cancer Res.
31. (2004). "High expression of precursor microRNA-155/BIC RNA in children with Burkitt's lymphoma". Genes Chromosomes Cancer.
32. (2004). "Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant Lymphoma". Cancer Res.
33. (2007). "MicroRNA signatures in human ovarian cancer". Cancer Res.
34. (2007). "MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis". JAMA.
35. (2008). "The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities". Nat Med.
36. (2008). "MicroRNA signatures in human ovarian cancer". Cancer Cell.
37. (2006). "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis". Cancer Cell.
38. (2005). "A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia". N Engl J Med.
39. Cho WC.. (2010). "A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia". Expert Opin Ther Targets.
40. (2010). "Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment". Mol Cancer Ther.
41. (2000). "Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia". N Engl J Med.